Overeem, Lucas Hendrik
Raffaelli, Bianca http://orcid.org/0000-0001-9758-1494
Mecklenburg, Jasper http://orcid.org/0000-0002-0777-0038
Kelderman, Tim http://orcid.org/0000-0003-4380-0721
Neeb, Lars http://orcid.org/0000-0002-1940-6399
Reuter, Uwe http://orcid.org/0000-0002-8527-0725
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Accepted: 5 June 2021
First Online: 16 July 2021
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL.
: LHO has nothing to disclose. BR has nothing to disclose related to the submitted work. BR reports grants from Novartis; personal fees from Novartis, TEVA, and Allergan. JM reports personal fees from Novartis, outside the submitted work. TH has nothing to disclose. LN has nothing to disclose related to the submitted work. LN reports personal fees from Novartis, Allergan, TEVA, and BIAL; personal fees from Hormosan, and Eli Lilly. UR has nothing to disclose related to the submitted work. UR reports personal fees from AbbVie, Allergan, Medscape, and StreaMedUp; personal fees and institutional fees from Amgen, Eli Lilly, and TEVA; grants, personal fees, and institutional fees from Novartis; institutional fees from Alder.
: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
: UR initiated the project. Study concept and design: LHO, LN, and UR. Acquisition of data: LHO and TK. Analysis and interpretation of data: LHO, BR, JM and TK. Drafting of the manuscript: LHO, BR, JM, and UR. Statistical analysis: LHO and JM. All authors read and approved the final manuscript, and agree to the accountable for the data and the accuracy of the data analysis.
: Not applicable.
: Not applicable.
: Not applicable.